Graphene-Dx, Point-of-Care Diagnostics

Graphene-Dx seeks to accelerate development of a graphene sensor based Covid-19 test platform using already established technology for graphene field effect sensors functionalized with antibodies for other analytes. 

Rapid response to emerging threats: The technology platform for binding antibodies to graphene sensors is mature, allowing new antibodies to be rapidly integrated onto the platform with high probability of success (typically<4 weeks once antibody selection complete).  This approach responds to the need for rapid development of  test platforms for existing and emerging health threats.

Technology: This technology has been successfully validated by detecting a wide variety of proteins and pathogens. Examples include, the cardiac marker troponin, hemoglobin and Chlamydia using graphene-based sensors functionalized with appropriate anti-troponin, anti-Chlamydia or anti-hemoglobin antibodies.

Scale-able Technology: This patented technology is a nano-bio combination technology can be scaled globally.  The chip is silicone based circuit coated with graphene and functionalized similar to an ELISA test.   

The COVID-19 pandemic has created a worldwide need to test the peoples of every country in the world,  perhaps,  more than once a day.  

The statistics for the number of people infected globally with COVID-19 at this writing is more than 5.5 million people with total death toll so far of over 350,000 persons.  We now know that many of the past pandemics, "... AIDS, SARS, MERS, Ebola and Marburg ... All of them are zoonoses, that is diseases of animal. They reach humans from wild animals with which we came into close contact through hunting and animal markets."* 

The next  yet unknown virus, will be a major problem in the future.  With the advent of faster and faster travel, and our continuous invasion of wild habitats, we are positioning the human race for many future yet unknown infections.  " In our global age, poor, unhealthy people infected with Covid-19 will remain sources of re-infection for wealthy, healthy people."*  

By offering a cheep disposable testing platform that can be re-purposed in weeks, we are hopeful that we can help in identifying, tracking and isolating the infected people and thereby help to contain this virus.

* WSJ, May 23,2020, Page C2.

We would like to re-purposing our platform to test for COVID-19.  The test platform, as it stands today, is able to rapidly (under 3 minutes) detect several proteins, bacteria and body markers, including Chlamydia, Troponin (a heart attack indicator), and hemoglobin (potential cancer indicators).  

No laboratory or a lab technician needed.  We could package the platform as a simple disposable cartridge costing under $3 USD and a Reader/Analyzer with a one time cost of under $200 USD or packaged in miniaturized in a packaged like a pregnancy test package for under $10 USD in volume.  The Reader/Analyzer is smaller than a shoe box now.

Graphene/Antibody Sensor:

The graphene sensor includes a chip with graphene layer that is deposited on an underlying substrate, e.g., a silicon substrate. A plurality of antibodies that exhibit specific binding to an antigen of interest are coupled to the graphene layer. Stable coupling of the antibodies to the graphene layer can be achieved by initially attaching a plurality of linkers to the graphene layer followed by covalently attaching the antibodies to the linkers.  

See figures above to see platform.  We been granted US  patents for our platform and have filled over 13 more provisional patent applications.  

The target population that can use our solution is every person that needs to be tested for COVID-19 or other analytes without the need to send the sample to a lab or use a lab technician.  Our solution will serve every person in the remotes parts of the world allow them to "self test"  and show the results in under 3 minutes on a local display AND will allow the data to be stored or transmitted through WI-FI  and/or cell phone to a central location for tracking and isolation purposes.

There can be two versions of our solution: Version 1 (currently in prototype) phase and working uses a desktop Reader/Analyzer with a screen that can accept a disposable cartridge and can be powered by a simple phone charger battery (USB) connection.  The cost to manufacture the cartridge can be as low as $3 USD and the Analyzer with one time cost of under $200 USD.  The second version, to be developed, will be a miniaturized version of the reader/analyzer , like an off-the-shelf pregnancy test kit that can manufactured in volume, for a cost of under $10 USD.

Our solution can be used almost anywhere: homes, restaurants, hospitals, etc.

The target population is any person that may require inexpensive, affordable healthcare related  testing while they lead their normal daily lives.  Our platform is  a point-of-care testing device that allows any person to be tested  in under 3 minutes and allows them to  safely participate in everyday life events.

Practical testing platforms must be accessible, affordable and accurately show the results.  Our solution can serve the populations of all nations with or without adequate healthcare systems.  We envision  a day when the any person can self test with little or no cost as often as needed for variety of infections.

Major patents have been granted to us by US the United States Patent Office for the graphene sensor platform.  We have over 15 pending patents for other analytes that can go on our sensor in addition to COVID-19 filing.  All patent documents are available for inspection under an NDA.

The unique aspect of our technology is graphene functionalized with a variety of antibodies using very innovative biochemistry solutions, innovative electronics to reduce circuit noise, and sophisticated processes that we have developed with scientists at Dana Farber Cancer Institute. We have used the latest nano technology at major universities to develop our chip manufacturing recipes  which is being migrated to industrial fabrication facilities.  Our prototype Reader/Analyzer is being designed to be miniaturized so that we can produce it in quantity similar to a pregnancy testing kit.

Our innovative process to functionalize the chips has been developed over the past 5 years by our scientists.  Our end process is comparable to the gold standard of lab testing using the ELISA process.  ELISA requires 3-4 hours and a specialized lab to run the tests, where, our sensor provides results in under 3 minutes without the need for a lab or specialized training.

We have produced a highly accurate, quick, and quantitative testing platform for variety of analytes at a very low cost price point.  Our device is a testing platform that we can put at the hands of any individual.  The data collected by our POC device can be saved and analyzed anytime.

We are using the unique electrical property of a single layer of carbon atom, called graphene that is layered  on a silicone chip.  Through a unique process, using "Linkers", we attached antibodies to the graphene.  Then when an antigen is presented in a sample to the "sandwich" layer, the graphene exhibits a "unique" electrical signature for that antibody/antigen/graphene covalent bond combination.  This signal is then captured and can be immediately  analyzed to determine if the targeted antibody-antigen has been detected.

Please see above pictures and graphs to see the technology.

Our technology consists of a graphene layer on a silicone wafer.  The circuit is then etched at a nano lab, it is then diced and each chip is tested for its electrical properties.  Once we are satisfied that each chip is working as expected, it goes to Dana Farber Cancer Institute to be functionalized for the planned test.  Our scientists then test the performance of the chip using positive and negative controls and compare them to a standard ELISA test. 

The scientists that have developed our platform in the last 5.5 years, are ALL highly experienced in their fields.  For example, Dr. Edward Greenfield, our antibody expert, is Director of Dana Farber Antibody  Core Laboratory. Dr. Mehdi Abedi, our chief scientist, is our expert in nano technology.  His PhD is in Mechanical Engineering and has an MS in Chemical Engineering.  Dr. Reza Mollaaghababa, out Patent Attorney, a Physics PhD, from Harvard and a practicing patent attorney. 

The basic science behind our technology is utilizing a change in one or more electrical properties of graphene that is deposited on an underlying silicon substrate and has been functionalized with one or more antibodies.   We have designed a "sandwich" combination that can detect a variety of antigens.  When a cartridge in which such a graphene-based sensor is incorporated is  plugged into the Reader/Analyzer,  a known voltage or current can be applied to the functionalized graphene layer and the electrical resistance of the graphene layer can be monitored.  The functionalized graphene layer will exhibit a change in its electrical resistance in response to the specific interaction (binding) of an antigen to the antibodies, thus allowing the detection of the antigen. By changing the antibodies, various antigens can be detected.  In fact, an array of sensors can be produced, where each sensor is functionalized with a different antibody for concurrent detection of different antigens.

We can detect the antigen in a "messy" solution without the need of extensive sample processing and are improving the sensitivity to detect at the picogram level..

The following data shows some test results obtained using our platform for the detection of troponin, hemoglobin and chlamydia:

A - Antibody-based troponin signal detection is achieved at greater than 4-fold compared to when an isotype antibody control is used.

B - Dose-dependent signal detection for hemoglobin is achieved at about 4-fold greater magnitude than isotype antibody control

C - Chlamydia protein detection in synthetic urine

We are in the process of trying to raise funds for volume manufacturing of our cartridges and to miniaturize our Reader/Analyzer.  We are confident that over the next few months we will have the funding to pursue our goal of being able to provide an affordable testing platform for the masses.  It is a platform that can be re-purposed in weeks to handle almost any current and future viruses and bacteria. When an individual is given the opportunity do a self test at very reasonable cost, they will be able to help contain any pandemic. 

Our patented sensor uses antibodies, bonded to a graphene layer on a silicone chip.  In order to detect the protein, pathogen, or antigen of interest,  the sample, usually on swab is immersed in a tiny vile containing an extraction solution and then a drop of that solution is placed on our cartridge This is very similar to a conventional blood glucose measuring device. The cartridge is then inserted into the Reader/Analyzer and if the antigen has bonded with the antibody, a diagnosis is made within 2-3 minutes.  

The social implication of this device is immense.  It can help keep population in ALL countries safe.  People will not be scared to socialize.  The social distancing of today may be unnecessary if an inexpensive, fast and accurate diagnostic test were available for all.

The key to opening of any economy after a pandemic is proper testing by all people.  Any infected or suspected to be infected person using a test kit like ours, can be quickly tested, tracked and quarantined if positive for the virus.

Using current methods, even if one tested negative for COVOD-19 today, does not mean they will not become positive tomorrow.  With a readily available cheap test, our test kit will allow friends, employers and coworkers to have confidence on the spot knowing that they are all virus free.  Everyone will be at ease interacting with each other.  Infected individuals will know to seek treatment or self-isolate, allowing others to return to a more normal way of life.

We are not currently serving any people as our solution will need FDA approval.  Once approved, we hope to serve as many people as possible as soon as we can scale by country, by continent and the locations of the greatest need.

Our business model calls for us to provide testing not only for COVID-19, but eventually for future yet unknown viruses,  Chlamydia, heart disease and a variety of cancers at an exceptionally affordable cost.

Since our solution does not need a lab or a lab technician, it can be exported to all parts of the world.  We envision each Reader/ Analyzer to display results in local languages as well as symbols.  Each unit can operate with a 5 volt battery.

We are hoping that people will carry the test kit and cartridges with them just like a pack of chewing gum. They will be able to test themselves  before they socialize in order to prove that they are not carrying dangerous viruses.

Based on our discussions with our chip manufacturer, we will be able to receive 10's of thousands of chips a day.  We will need to use current drug manufacturing machines to functionalize our chips.  That will depend the funding level that we are able to obtain.  Our Reader/Analyzer can easily scale to the volume needed as more and more people choose to carry Reader/Analyzer in their pockets and carry appropriate disposable cartridges with them, depending on the pandemic.

Our goal for the balance of 2020 and into mid 2021 is to find a suitable partner and/or raise sufficient funds to package and miniaturize our sensor and get FDA approval.  Since our solution is an "external" use point-of-care device, and not a ingest-able drug, the FDA process should be minimal.

Once we have the FDA approval, we will begin volume manufacturing the sensor and partner with medical distribution companies to distribute the device and its cartridges.  Our existing owners/partners have long established medical distribution partners that have shown interest in carrying our sensor in their catalogs.

Over the next five years, we are hoping to provide our solution for all the peoples of the world, especially the under privileged and under-served.  We hope that countries that don't have a robust health system, will be especially pleased to offer our solution along with proper hygiene programs to the remotest parts of their countries. 

The Graphene-Dx partners have pledged that a. The device will be affordable and b. a portion of the profits will be donated to help provide free test kits. 

We hope to begin distribution in Europe over the next 2-3 years while we use that experience to provide the platform for Asia, middle east and Africa. We will consider local manufacturing where feasible and will consider licensing the technology for local manufacturing as learn more about the needs of the local community.

Our only barrier is getting adequate funding.  We have some of the best scientists who are also partners at Graphene-Dx.  They have a vast experiences in each of their areas of expertise and are highly respected by their colleagues.

After almost 6 years of research with an amazing team, we have been able in invent a platform that can help humanity is a very large scale in healthcare, agriculture and other ares of daily life.  Our goal in 2020/2021 is to receive $5M in funding to set up up and another major round in 2022 once we start distributing our product. 

We are currently busy testing various bacteria to ensure we have re-produciblity and high sensitivity.  Both objectives are very much within reach.  

We also have small hurdle of FDA approval.  We don't anticipate too much of a problem as our device is an external device to the human body and no patient will be given any medications to ingest or will need to have a medical procedure.

The major barrier is funding for the next year to 18 months as we accumulate test results to go for round B funding.  Many of the hurdles, such as volume manufacturing, distribution and business experience have already been researched and available or they exist within the company.  

In summary, we need funding to globally scale our  revolutionary sensor and provide a practical way for people to resume normal life again.    

Barrier 1: Funding

We have been self funded by our partners and continue to receive some funding as needed.  However, we will be approaching major bio and pharma companies as well as venture capital for round A funding of about $5M.  We have put together "pitch decks" and will begin doing road shows in 2021.

Once we receive pledges from the partner companies and or private equity/VC, we will begin preparation for Round B funding is spring of 2021.

We expect to have our own lab in the Fall of 2020 and hire full time staff at that time.    

Barrier 2: Testing 

Once we get some funding, we intend to accelerate testing for COVID-19 and Chlamydia.  We are very close to complete the chlamydia testing.  We see each cartridge as an revenue source to fund development of other cartridges.  However, we will need our own small lab in order to reduce testing costs.  When we overcome Barrier 1, we will resolve barrier 2 as well. 

Since  we have already created our own unique monoclonal antibodies for gluten at Dana Farber, we learned the testing  process and we are confident that we can deploy resources to create new monoclonal antibodies as needed. 

We have 8 team members and two consultants.  All team members are part owners of Graphene-Dx.

One of the Founders, Namal Nawana, has had several CEO positions in global healthcare companies.  In his latest role, he was CEO of Alere, a molecular diagnostics company with sales of several billion dollars a year.

Our chief scientist is Dr. Mehdi Abedi, teaching professor at Northeastern university and an expert in chip manufacturing.

Our antibody expert is highly regarded Dr. Edward Greenfield, currently Director of Dana Farber Core Laboratory in Boston.

The rest of the team includes Electrical Engineer and patent attorney.

 
Our Team members are owners and experts in their field:

Namal Nawana, Founder, is a business leader and Healthcare entrepreneur with a particular focus in the Medical Devices and Diagnostics industry.

 Mr. Nawana has extensive experience leading global public companies and was formerly Chief Executive Officer and a member of the Board of Directors of Smith & Nephew Plc, based in the United Kingdom and Chief Executive Officer and member of the Board of Directors of Alere inc.  a NYSE listed company, until its $8 billion acquisition by Abbott Laboratories in 2017.

Mr. Mohammed Fotouhi, founder and innovator, has had over 40 years of starting, running and selling successful high tech businesses.  His role is to lead the scientific team in pursuit of company objectives.  He is the principal inventor of the technology used at Graphene-Dx

Our chief antibody specialist is Dr. Edward Greenfield:

Scientist/consultant with industry and academic expertise in research & development related to hybridoma technology and/or immunology development.  Ed Greenfield became the Technical Director of the Dana Farber/HCC Monoclonal Antibody Core in 2009, bringing 25+ years academic and industry experience generating monoclonal antibody hybridomas to this position. He has led monoclonal antibody programs at Repligen, Millennium and Abpro prior to taking a leadership role in the Monoclonal Antibody Core.  

Dr. Mehdi Abedi, Professor of Mechanical Engineering, Northeaster University.  Dr. Abedi is in charge of our chip manufacturing unit.

Dr. Reza Mollaaghababa, PhD, Physics, Harvard University, our patent attorney as well scientific advisor.

We currently work with Dana Farber Cancer Institute to develop our various antibodies as well functionalize and test our silicone chips. Dr. Greenfield manages our relationship with Dana Farber. 

We work with  Harvard University Nano Lab and Northeaster University Nano Lab to manufacture our chips.  Dr. Mehdi Abedi manages our relationship with the consultants that manufacture the chips.

We work with Groltex, Inc. as our graphene processor.  They deposit graphene on our silicone wafers according to our specialized recipes.

One of partners, Mr. Kavandegar, EE, is designer of our Analyzer/Reader device.  He works with Zeta Electronics in New Hampshire to produce the various versions of our patented ICs.

Our Patent legal office is Nutter, Mclenen and Fish, in Boston.  Dr. Reza Mollaaghababa drafts and manages the writing and submission of our patents by Nutter.  

Since graphene is a unique natural material, working with it require very specialized facilities and equipment.  Our unique chip manufacturing processes as well as the chip fictionalization process require us to work closely with volume manufacturers, which we are talking to.

We are also working with an electronics company to miniaturize our Reader/Analyzer unit so that the entire kit, namely, the cartridge(s) and the  Reader/Analyzer unit will fit into a 3" X 2" X.5" box that can easily be carried by an individual.

Our founder, Mr. Nawana has extensive relationship with medical device and drug distribution companies.  They will provide our product through their established channels.  We will establish our own channels in the developing world.

We are a Massachusetts LLC operating in a research and development mode since January 2014.  We have been funded by our founders so far and hope to partner with larger companies that will help us scale our solution to all of the people of the world within the next 5 years. 

Since our incorporation, we decided to create a testing platform with latest technology and materials for a point-of-care diagnostic device that would not need a lab to process the results.  We have achieved this objective.  

In order to achieve our objective we have used various educational institution clean rooms and labs to make our chips, functionalize them and do the testing. 

Once we choose a suitable major corporate partner, we may become part of that larger entity but will maintain our goal of: providing low cost testing products while donating a portion of the profits help pay for those who cannot afford the test kits.

Once we scale to a global scale, we are confident that we can our achieve our objective of offering a low cost testing platform for any individual to help test, track and quarantine infected people.

Our business model calls for donating a portion of our profits to help those that cannot afford to pay for the kits and we will also donate free test kits as needed to people who cannot afford it.

It is time that individuals had the tools to self test at a low cost price point as often as needed. 

Over the last 5.5+ years, we have been able to develop a major point-of-care testing platform that can be produced inexpensively, it is very accurate and practical to use.  This has happened because our founder and innovator, Mr. Fotouhi has had over 35 years of successfully building and operating high tech businesses.  We have been able to attract some of the brightest scientific minds to Graphene-Dx while maintaining a very lean organizational structure.

We have had the financial expertise to manage the company with limited funds and have retained every member of the team from day 1 to today.  Our owners have raised equity for their companies in the past and will do the same going forward.

We hope to raise $5,000,000 USD in 2020-2021 so that we can get to volume production the later half of 2021.  Once we have achieved that goal, we intend to go for Round B financing and begin to generate revenue by 2022.

We strongly believe that we can grow the company while investing in technology to bring our production cost down.

The number of test kits needed in this and futures pandemics will be in 10s of million kits a month.

"The global point-of-care diagnostics market is projected to reach USD 46.7 billion by 2024 from USD 28.5 billion in 2019, at a CAGR of 10.4% during the forecast period." according to Marketsandmarkets, Inc. Northbrook, Ill 60062.

Going forward post 2020 Covid-19, every man, woman and child will need to be tested!

Over approximately last 6 years we have developed  THE state of the Art  point-of-care (POC) diagnostic tool.  Our invention will revolutionize testing and will make rapid accurate testing available in the remotest parts of the world at an affordable cost.

Our team consists of some of the brightest and accomplished scientists and executives known in this industry.  We own our own IP and have NOT licensed any piece of our invention from a third party.

Our barrier at this time is obtaining funding for large scale manufacturing and distribution.  We will also need to get FDA approval which entails costs. 

Chip Manufacturing:  We have contacted several chip manufacturing facilities and very few have worked with graphene before.  However, we have identified several that can follow our recipe to mass produce the chips coated with graphene.

Miniaturization:   We have worked with IC manufacturers in building a prototype Reader/Analyzer unit based on Raspberry Pi platform with WiFi and Bluetooth.  There are several companies that take our 6" x 4" x 3" box and make the size of a small glucose monitor. The miniaturized Reader/Analyzer will be smaller than a US $.25 coin.

Fuctionalization:  The process of binding antibodies on graphene has been the most challenging part of our research and development and we have created a unique process that allows antibodies to bind with the graphene via "linkers" applied in a proprietary way.  We will need to build a device a new machine that can do the fictionalization in volume.

Over the last 5-6 years not only we have developed our technology, but have also established working relationship with our potential supply chain partners. Our potential partner, if needed,  can use our supply chain for volume production as needed.

Example of companies we can potentially partner with are:

• Abbott (US)
• Roche (Switzerland)
• Siemens (Germany)
• Danaher (US)
• Becton, Dickinson, and Company (US)
• Neogen
• Boston Scientific
• Exact Sciences
• Johnson & Johnson (US) and many more...  

Although we will consider financial partners/venture funding, we believe that a company in the healthcare industry may create a special entity that can achieve our goal of enhancing healthcare of  the under privileged people of the world.  Ideally, a financial funding entity in partnership with a healthcare provider may be the best possible outcome.  

Ideally, a molecular diagnostics company that has a history of developing, marketing selling  and supporting consumer kits while being socially responsible. 

Although the following companies will be a great home for our invention, we welcome any and all participation from MIT, its faculty, students and the entire MIT technical organization, especially Draper Labs.

• Abbott (US)
• Roche (Switzerland)
• Siemens (Germany)
• Danaher (US)
• Becton, Dickinson, and Company (US)
• Neogen
• Boston Scientific
• Exact Sciences
• Johnson & Johnson (US) and many more...  
• Venture funds, such as AVG Alumni Venture Group

We are particularly interested in a one day seminar between our scientists and interested MIT scientists, students and Lab directors.

We have been granted the broadest patents on our technology and would be happy to exchange our experiences with the entire MIT community.  This is a company that has built its patented product without outside investors and without any government funding.

We envision an corporate board, where 1-2 founding members of Graphene will have a seat.  Also, we envision a technical advisory broad that would suggest improvements and collect data to identify the next pandemic.

MIT's Draper lab can be a very important partner, especially for designing our prototype for pre-manufacturing design assistance, going forward.

We are also interested in talking with Venture funds in the rapid molecular diagnostics space. 

We are uniquely positioned to apply for this prize.  Our entire goal has been to create a state-of-art point of care, with rapid response capability that is affordable, portable and practical.  People would be encouraged to carry this device and a few cartridges just like a pack of chewing gum. 

This device, used properly, that can literally save millions of lives by providing a way  to test easily and  carrying it in one's pocket, can become second nature for daily routine.

COVID-19 is the last virus to show itself.  We will most likely have other pandemics in the future.  But now, we have a platform that can be useful in weeks and will not need a lab.  This is THE versatile point-of-care testing device at its best!

The most important aspect of our platform is that our chip can be functionalized with protein or DNA/RNA providing the ability for detecting serology testing for antibodies and DNA/RNA for cancer detection!  We can use Nasal swab, vaginal swab, blood/serum, saliva, urine or fecal sample.

Our entire approach has been to have single use disposable cartridges.  Our future miniaturized version can be developed such that ALL parts are disposable.  We hope to develop a version of our cartridge that will not need refrigeration.  The technology to keep the anybodies dormant is available.

Since our platform is Internet-of-Things (IoT), we can expand our current App on the iphone track an infected person and get them help and quarantine them.

Graphene-Dx is  uniquely qualified for this prize because our sensor platform has the potential of providing life saving technology to very woman, man and child at little or no cost, depending on the programs available at different countries.

We  are able to create monoclonal antibodies (through our partners, such Dana Farber Cancer Center) in weeks and to functionalize our sensors.  We can functionalize our sensors with proteins or DNA/RNA.  This give us the ability for detecting serology testing for DNA/RNA for cancer testing. 

With funding, we can scale to  meet the demand.  Our vision is to put one of our sensor kits in every pocket/school bag and every purse so that people can self test as needed go on with their new normal life.

We will need help in setting up our crowd funding capability.  We hope that MIT can help us if/when we get to that point.

Our biggest challenge is funding to start manufacturing to scale as needed so that  we can respond to crisis at volume and be able to divert from current late stage developments such as (Chlamydia).

Working with graphene for the approximately past 6 years, has resulted in several major patents as well as many filed patents that are in the process of being reviewed.  We have learned that although several graphene based sensors  have been developed in the lab, very few, if any use antibodies to functionalize the chip and,more importantly, the samples are primarily conjugated with a  metal and analyzed color-metrically. That is, the sample, usually requires preprocessing and addition of  'tags" to identify the binding of the antigen.

Our platform does need preprocessing of the test sample.  we envision our kit to contain swabs and cartridges and be smaller than a package of gum or chocolate that can be transported in one's pocket.

We believe that we have created the most advanced and practical molecular diagnostic device which can have a global impact within 2-5 years.  Although there are many point-of-care (POC) testing devices in the market,  we are not aware of a rapid, accurate and affordable antibody testing device that can operate without a trained technician or one that does not need  the sample to be sent to a lab.

Imagine a world where as part of a daily routine, a person can carry a testing kit and be able to do a self test and show the results to friends and colleagues in under 3 minutes and continue to meet and  socialize without a face mask if the results are negative.  

Our testing results of the past 5 years are available to be examined and we will provide our scientists and engineers to discuss our technology under and NDA.